ES2199358T3 - Uso de clotrimazol y compuestos relacionados en el tratamiento de la diarrea. - Google Patents

Uso de clotrimazol y compuestos relacionados en el tratamiento de la diarrea.

Info

Publication number
ES2199358T3
ES2199358T3 ES97916035T ES97916035T ES2199358T3 ES 2199358 T3 ES2199358 T3 ES 2199358T3 ES 97916035 T ES97916035 T ES 97916035T ES 97916035 T ES97916035 T ES 97916035T ES 2199358 T3 ES2199358 T3 ES 2199358T3
Authority
ES
Spain
Prior art keywords
group
hskip
phenyl
diarrhea
clotrimazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97916035T
Other languages
English (en)
Spanish (es)
Inventor
Wayne I. Lencer
Carlo Brugnara
Seth Alper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Application granted granted Critical
Publication of ES2199358T3 publication Critical patent/ES2199358T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065—Diphenyl-substituted acyclic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39508—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from milk, i.e. lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES97916035T 1996-03-20 1997-03-20 Uso de clotrimazol y compuestos relacionados en el tratamiento de la diarrea. Expired - Lifetime ES2199358T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/621,169 US5889038A (en) 1996-03-20 1996-03-20 Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
US621169 1996-03-20

Publications (1)

Publication Number Publication Date
ES2199358T3 true ES2199358T3 (es) 2004-02-16

Family

ID=24489031

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97916035T Expired - Lifetime ES2199358T3 (es) 1996-03-20 1997-03-20 Uso de clotrimazol y compuestos relacionados en el tratamiento de la diarrea.

Country Status (9)

Country Link
US (3) US5889038A (enExample)
EP (1) EP0910376B1 (enExample)
JP (2) JP2000506895A (enExample)
AT (1) ATE245981T1 (enExample)
DE (1) DE69723843T2 (enExample)
DK (1) DK0910376T3 (enExample)
ES (1) ES2199358T3 (enExample)
PT (1) PT910376E (enExample)
WO (1) WO1997034599A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU732881C (en) 1994-09-16 2002-11-07 Children's Medical Center Corporation Triaryl and diaryl compounds, their analogues and uses thereof
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5889038A (en) * 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
US6667063B2 (en) * 1998-06-10 2003-12-23 Albert Crum Nutritional or therapeutic supplement and method
JP4394451B2 (ja) * 2002-01-04 2010-01-06 ニューロサーチ、アクティーゼルスカブ カリウムチャネルモジュレーター
US20050175597A1 (en) * 2002-03-21 2005-08-11 Rawlin Grant T. Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment
US10066254B2 (en) * 2002-05-20 2018-09-04 Cedars-Sinai Medical Center Diagnosis of constipation by analysis of methane concentration
CA2771788C (en) 2002-05-20 2022-03-22 Cedars-Sinai Medical Center Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration
EP1667632A4 (en) * 2003-09-18 2009-07-01 Childrens Medical Center TREATMENT OF HEAVY DISTAL COLITIS
US20060013890A1 (en) * 2004-06-24 2006-01-19 Green Shawn J Dairy-derived anticholesterol immunoglobulin to lower dietary cholesterol in humans
US20070087002A1 (en) * 2005-10-14 2007-04-19 Green Shawn J Anticholesterol immunoglobulin to treat lipid raft diseases
KR101560844B1 (ko) * 2007-06-04 2015-10-15 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 트라이-아릴계 화합물 및 이를 포함하는 조성물
ES2358564T3 (es) 2007-08-24 2011-05-11 Neurosearch A/S Derivados de carbonilamino útiles para el tratamiento de una enfermedad inflamatoria intestinal.
KR101345860B1 (ko) 2011-10-25 2013-12-30 이화여자대학교 산학협력단 모다피닐 또는 이의 유도체를 포함하는 혈관질환 치료용 조성물
US9289418B2 (en) 2013-03-15 2016-03-22 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
JP2016516717A (ja) 2013-03-15 2016-06-09 シーダーズ−サイナイ メディカル センター メタン細菌に起因または関連する疾患および状態を診断、選択、および処置する方法
CN103266281B (zh) * 2013-05-24 2015-02-04 无锡鑫常钢管有限责任公司 一种超级双相不锈钢管及其生产工艺
MX2016005995A (es) 2013-11-05 2016-08-17 Ben-Gurion Univ Of The Negev Res And Dev Authority Compuestos para el tratamiento de diabetes y complicaciones de la enfermedad derivadas de la misma.
KR102425303B1 (ko) 2014-08-13 2022-07-25 세다르스-신나이 메디칼 센터 항-메탄생성 조성물 및 그것의 용도
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
US12390473B2 (en) * 2019-01-16 2025-08-19 The Regents Of The University Of California Methods of treating tyrosine kinase inhibitor-induced diarrhea
JP6664637B1 (ja) * 2019-08-08 2020-03-13 株式会社 レオロジー機能食品研究所 ストレス低下用及び／又は体重回復用経口組成物、並びにプラズマローゲン含有組成物の製造方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US307874A (en) * 1884-11-11 Bessemer converter
US3655882A (en) * 1968-08-26 1972-04-11 Staley Mfg Co A E Stable dietary supplement for new born pigs
US3965112A (en) * 1971-01-11 1976-06-22 John Wyeth & Brother Limited Imidazoline derivatives
CA1007568A (en) * 1973-12-13 1977-03-29 Canada Packers Limited Bovine immunoglobulin isolation process
US3917615A (en) * 1974-04-01 1975-11-04 Searle & Co 1,1-Diaryl-1-oxadiazol-alkylamines
US3998832A (en) * 1975-04-16 1976-12-21 G. D. Searle & Co. Anti-diarrheal compounds
US4284829A (en) * 1977-09-13 1981-08-18 Pfizer Inc. Hydroxyalkyl and oxoalkyl substituted phenols as analgesics and sedatives
US4806685A (en) 1985-08-05 1989-02-21 Gyogyszerkutato Inteezet/Pharmaceutical Research Institute 1,1,2-triphenylpropane and -propene derivatives
JPS62163662A (ja) * 1986-01-11 1987-07-20 Nippon Nousan Kogyo Kk 犬猫用ペツトフ−ド
WO1989005654A1 (en) 1987-12-24 1989-06-29 California Biotechnology Inc. Linear analogs of atrial natriuretic peptides
AU629559B2 (en) * 1988-08-04 1992-10-08 Thomas Julius Borody Oral antibody therapy for patients with lowered immune response and composition therefor
AU5254790A (en) * 1989-04-06 1990-10-11 Chugai Seiyaku Kabushiki Kaisha Process for preparing a therapeutic agent for rotavirus infection
AU7687091A (en) * 1990-04-09 1991-10-30 Medicis Corporation Antidiarrheal composition and method
DE4130689A1 (de) * 1991-09-14 1993-03-18 Biotest Pharma Gmbh Verfahren zur herstellung eines leicht loeslichen getrockneten immunglobulin-praeparats aus kolostralmilch
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
US5387600A (en) 1992-07-30 1995-02-07 Fuji Photo Film Co., Ltd. Treating arteriosclerosis using benzimidazole compositions
US5512591A (en) 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
US5439086A (en) * 1993-12-10 1995-08-08 Oceaneering International, Inc. Mechanical clutch
FR2715068B1 (fr) * 1994-01-17 1996-04-19 Paul Vidal Procédé permettant de recueillir des doses de sérocolostrum bovin destinées à être administrées par voie orale à des veaux nouveau-nés ainsi que dispositif permettant la mise en Óoeuvre de ce procédé.
US5650425A (en) 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
AU2880595A (en) 1994-07-06 1996-01-25 Bo Arne Hofmann Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
WO1996008242A2 (en) * 1994-09-16 1996-03-21 Children's Medical Center Corporation Clotrimazole metabolites in the treatment of sickle cell disease
AU732881C (en) 1994-09-16 2002-11-07 Children's Medical Center Corporation Triaryl and diaryl compounds, their analogues and uses thereof
US5889038A (en) 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
WO1999025347A2 (en) 1997-11-14 1999-05-27 Neurosearch A/S Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction

Also Published As

Publication number Publication date
DE69723843T2 (de) 2004-03-04
JP2009007368A (ja) 2009-01-15
US6495567B1 (en) 2002-12-17
US20030119784A1 (en) 2003-06-26
US5889038A (en) 1999-03-30
EP0910376A2 (en) 1999-04-28
ATE245981T1 (de) 2003-08-15
WO1997034599A3 (en) 1998-02-12
JP2000506895A (ja) 2000-06-06
WO1997034599A2 (en) 1997-09-25
PT910376E (pt) 2003-12-31
EP0910376B1 (en) 2003-07-30
DK0910376T3 (da) 2003-11-17
DE69723843D1 (de) 2003-09-04

Similar Documents

Publication Publication Date Title
ES2199358T3 (es) Uso de clotrimazol y compuestos relacionados en el tratamiento de la diarrea.
ES2260857T3 (es) Uso de compuestos de aminotiol para el tratamiento de trastornos neurologicos y nefrologicos y toxicidades terapeuticas.
ES2699646T3 (es) Compuestos para uso en el tratamiento de enfermedades mediadas por acuaporina
BR112019027454A2 (pt) uso de canabidiol
BRPI0717859A2 (pt) mÉtodos para aumentar a biodisponibilidade de um composto de 5-aminossalicilato, para aumentar a biodisponibilidade de 5-asa para o càlon de um indivÍduo, para retardar o trÂnsito de 5-asa no càlon de um indivÍduo, para diminuir o nÍvel sistÊmico de 5-asa em um indivÍduo, para diminuir a concentraÇço plasmÁtica mÁxima de um composto de 5-aminossalicilato em um indivÍduo, para retardar a tmax de um composto de 5-aminossalicilato em um indivÍduo, para diminuir o grau de absorÇço de um composto de 5-aminossalicilato em um indivÍduo, para aumentar a razço sistÊmica de nasa para 5-asa em um indivÍduo, para aumentar a conversço de 5-asa para nasa em um indivÍduo, para diminuir a taxa e grau de absorÇço de uma forma de dosagem oral de balsalazida, para usar balsalazida, e, para inibir o crescimento de uma espÉcie bacteriana em um indivÍduo humano
CN104093410B (zh) 用于治疗腹泻的物质和方法
PT2127652E (pt) Agente libertador da hormona estimuladora dos folículos
Cuppoletti et al. Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors
Satoh et al. Proton pump inhibitors prevent gastric antral ulcers induced by NSAIDs via activation of capsaicin-sensitive afferent nerves in mice
de Souza Goncalves et al. Mg 2+ supplementation treats secretory diarrhea in mice by activating calcium-sensing receptor in intestinal epithelial cells
ES2266610T3 (es) Composiciones que comprenden epotilonas y su uso en el tratamiento del sindrome carcinoide.
EP4051232A1 (en) Liquid oral formulation of bumetanide
Gamboa‐Vujicic et al. Toxicity of the mitochondrial poison dequalinium chloride in a murine model system
US6291449B1 (en) Use of 11-phenyl-dibenzazepine compounds to treat diarrhea or scours
Pearce et al. 2, 3-Dihydroxybenzoic acid: Effect on mortality rate in a septic rat model
BR112020017835A2 (pt) Agente de tratamento de epilepsia
Hudson et al. Prostaglandin E in cholera toxin-induced intestinal secretion: Lack of an intermediary role
TW586927B (en) Compositions and combinations for the prevention and treatment of gastrointestinal disorders
Novak et al. Fundamentals of bicarbonate secretion in epithelia
ES2343060T3 (es) Una combinacion que comprende levosimendano y una fuente de calcio para el tratamiento del fallo cardiaco.
Ti et al. Chloramphenicol concentrations in sera of patients with typhoid fever being treated with oral or intravenous preparation
Hutcheon et al. Therapeutic efficacy of diuretics with different durations of action
Whitehouse et al. Prevention of the gastrotoxicity of aspirin and related drugs in rats by lithium salts and sodium thiocyanate
US20020004519A1 (en) Method for reducing chloride secetion by intestinal epithlial cells in situ
ES2264444T3 (es) Composicion farmaceutica que comprende furosemida y conivaptan para el tratamiento de insuficiencia cardiaca congestiva.